Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve

• Published in: Cancer medicine (Malden, MA) Vol. 12; no. 3; pp. 2646 - 2657
• Main Authors: Tomonari, Tetsu, Tani, Joji, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Asahiro, Morishita, Okamoto, Koichi, Sogabe, Masahiro, Miyamoto, Hiroshi, Muguruma, Naoki, Masaki, Tsutomu, Takayama, Tetsuji
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2023; John Wiley and Sons Inc; Wiley
• Subjects: Albumins; atezolizumab; Bevacizumab; Bilirubin; Cancer therapies; Carcinoma, Hepatocellular; Drug therapy; Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Humans; Immunotherapy; Liver cancer; Liver Neoplasms; Monoclonal antibodies; Multivariate analysis; Patients; Response rates; Solid tumors; Targeted cancer therapy; Tumors; bevacizumab; atezolizumab; hepatocellular carcinoma

Aim We analyzed the association between the modified albumin–bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u‐HCC). Methods In this retrospective observational study, we included 71 u‐HCC patie...